A Critical Evaluation of Octreotide Capsules in Acromegaly - Long Island, NY

Garden City, NY US

Take advantage of this regional CME opportunity to learn about options for the treatment of acromegaly including a new medical therapy, oral octreotide. Sponsored by the Endocrine Society, 30 Regional CME Dinner Events will be held in cities across the US, each dinner event will feature a one-hour CME presentation followed by discussion with an expert on treating patients with acromegaly.

Target Audience

The target audience for this educational content is endocrinologists, neurosurgeons, fellows, residents and allied healthcare providers.

Learning Objectives

As a result of participating in this activity, learners should be able to:

  • Explain efficacy and safety outcomes associated with control of GH/IGF-I levels and amelioration of signs/symptoms
  • Educate patients in successful and safe management of their disease using an oral therapeutic alternative
  • Understand and share latest clinical developments in oral treatment of patients with acromegaly

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Adrenal/HPA Axis
Quality Improvement and Healthcare Delivery
General Endocrinology
Neuroendocrinology and Pituitary
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
Course expires: 
Maggiano's Little Italy
600 Garden City Plaza
Garden City, NY 11530
United States


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
John Carmichael, MD: Consultant, Pfizer, Chiasma; Speaker, Novartis; Investigator, Novartis, Pfizer, Novo Nordisk, Chiasma
Maria Fleseriu, MD, FACEInvestigator, Chiasma, Cortendo, Ipsen, Novartis, Pfizer; Consultant, Chiasma, Cortendo, Ipsen, Novartis, Pfizer
Adriana Ioachimescu, MD: Investigator, Ipsen, Novartis, Chiasma; Consultant, Ipsen, Ionis, Chiasma
Lisa Nachtigall, MD: Consultant, Genentech, Chiasma, Ipsen; Speaker, Chiasma, Novartis; Investigator, Ipsen

Disclosure information for presenters is included in their individual recorded presentations.

The following planners reported relevant financial relationships:
Pamela Freda, MD (Chair): Speaker, Chiasma; Investigator, Novartis, Chiasma, Pfizer, Ipsen
Lawrence Frohman, MD (Chair): Speaker, Chiasma
Shlomo Melmed, MD (Chair): Consultant, ISIS Pharma, Chiasma, Novartis, Strongbridge; Research grant, Ipsen, Pfizer, Inc.
Lisa Nachtigall, MD: Consultant, Genentech, Ipsen; Principal investigator, Ipsen; Speaker, Chiasma, Novartis
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sara Berga, MD: Advisory board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media LLC, Shionogi, Inc.
Paresh Dandona, MD: Consultant, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk; Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research grant support, Amgen, Eli Lilly, Merck
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo Umpierrez, MD: Advisory board, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research grant support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron
John Carmichael, MD: Consultant, Pfizer, Chiasma; Speaker, Novartis; Investigator, Novartis, Pfizer, Novo Nordisk, Chiasma

The following planners reported no relevant financial relationships:
Natalie Cusano
Michael Irwig
Alan Kelly
Connie Newman

The following peer reviewers reported no relevant financial relationships:
Larry Fox, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This educational activity is supported by an independent medical educational grant from Chiasma, Inc.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation